SANA
MVD-1 — nitroalkene / salicylate derivative
SANA (MVD-1 — nitroalkene / salicylate derivative) is a metabolic & fat loss research compound. Sold as a nitroalkene / salicylate derivative studied for creatine-associated thermogenesis and mitochondrial substrate handling. The creatine angle is the interesting part: creatine cycling between phosphocreatine and creatine can act as a futile cycle that burns ATP as heat rather than storing it, and that is a genuinely different fat-loss lever from appetite suppression or beta-adrenergic stimulation. Everything in that sentence comes from the vendor's own description. No published pharmacology for MVD-1 was found.
SANA quick facts
| Route | Oral |
| Frequency | 1x Daily |
| Half-life | Unknown |
| Forms | Oral |
| Evidence level | None independent — vendor description only. No PubMed entry, no trial registry record. |
50MG per capsule, 60 capsules per bottle, $149.99. The honest position: this is a compound with a mechanism story and no data behind it. Treat the thermogenesis claim as a hypothesis somebody is selling, not a finding. One credibility signal worth knowing: DA's own 'research guide' page for SANA contains no CAS number, no formula and no mechanism — just keyword strings like 'insane fat burner' and 'weight loss pill'. Every other compound in this batch has a real reference page. That tells you how new and how unsubstantiated this is.
How SANA works
Sold as a nitroalkene / salicylate derivative studied for creatine-associated thermogenesis and mitochondrial substrate handling. The creatine angle is the interesting part: creatine cycling between phosphocreatine and creatine can act as a futile cycle that burns ATP as heat rather than storing it, and that is a genuinely different fat-loss lever from appetite suppression or beta-adrenergic stimulation. Everything in that sentence comes from the vendor's own description. No published pharmacology for MVD-1 was found.
Proposed benefits
Researched for fat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
Where to get SANA
Buy SANA at Disguised Alpha →The evidence for SANA
Graded by what exists behind each claim.
✅ Clinically validated
- None. No PubMed entry, no trial registry record, no published pharmacology for MVD-1. Everything on this page describing what it does comes from Disguised Alpha's own product listing.
📊 Correlative data
- The nearest real evidence is the creatine futile-cycle literature itself — the observation that cycling between creatine and phosphocreatine can burn ATP as heat rather than storing it. That work is about the pathway, not about this molecule, and no published link connects the two.
🧪 Theoretical / extrapolated
- Sold as a nitroalkene / salicylate derivative acting on creatine-associated thermogenesis and mitochondrial substrate handling. If that is accurate, it is a genuinely different fat-loss lever from the two the market already has — it would raise heat production rather than suppress appetite (GLP-1s) or drive beta-adrenergic output (clen).
- That 'if' is carrying the whole page. A mechanism story with no data is a hypothesis someone is selling at $149.99. DA does not publish a per-capsule strength, so there is not even a dose to reason about.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What SANA actually does
The mechanism being sold here is real science. It is also contested science, and there is no published evidence connecting it to the molecule in the capsule. Those are three separate statements and this page keeps them separate.
What the futile creatine cycle actually is. Creatine kinase normally buffers cellular ATP: it moves a phosphate from phosphocreatine onto ADP when demand spikes, and back when demand falls. A futile cycle is what happens when that phosphorylation and dephosphorylation run continuously in opposite directions without doing any external work. Each turn hydrolyzes ATP, and the energy leaves as heat. That is thermogenesis without uncoupling protein 1 — a completely different lever from appetite suppression or beta-adrenergic drive, and it is the reason the idea is interesting Brownstein 2022 Kazak 2023.
The strongest evidence for it, and it is recent and good. Reintroducing mitochondrially-targeted creatine kinase B into UCP1-deficient mice restored thermogenesis and cold tolerance, which is about as direct a demonstration as this field can produce that the cycle carries real physiological heat Bunk 2025.
And the strongest evidence against it, from the same literature, which the vendor page does not mention. Creatine supplementation did not stimulate respiration in cultured adipocytes, in isolated mitochondria, or in permeabilized white adipose tissue; and ablating Ckmt1 in mice did not alter energy expenditure or the metabolic response to beta-3 adrenergic activation, leading the authors to call that kinase dispensable Politis-Barber 2022. So which creatine kinase carries the cycle, in which fat depot, and whether feeding creatine engages it at all, are open questions being argued in the primary literature right now. A product sold on this mechanism is being sold on an argument its own field has not finished having.
What the molecule itself is, chemically. A nitroalkene is an electrophile — a carbon-carbon double bond carrying a nitro group, which makes the beta carbon strongly electron-poor and therefore reactive toward soft nucleophiles. In a cell the soft nucleophiles are cysteine thiols. So a nitroalkene does not bind a receptor; it forms reversible Michael adducts with cysteines on whatever proteins it reaches first, and its signaling is the sum of those adducts Grippo 2021. The salicylate half is a separate pharmacology again: sodium salicylate rewires hepatic metabolic pathways in obesity and attenuates interleukin-1 beta secretion from adipose tissue Kajani 2022. Neither of those two chemistries has ever been linked in print to creatine cycling.
Cell, rodent, human — and where it stops
Step one, in cells and isolated mitochondria — and the step is split. On the creatine side, the cycle is demonstrable in brown adipose mitochondria and the case for it as a genuine thermogenic pathway is now made in a mouse rescue experiment Bunk 2025. Against it, a careful negative study across cultured adipocytes, isolated mitochondria and permeabilized tissue found no creatine-stimulated respiration at all Politis-Barber 2022. Both are cell-and-rodent work. Neither is about a person.
On the nitroalkene side, the cell data is about chemistry rather than about fat. Fatty acid nitroalkenes have measured electrophilicity rankings — nitro-conjugated linoleic acid far more reactive than nitro-linoleic, which is more reactive than nitro-oleic — and measured critical micellar concentrations of 6.9, 10.6 and 42.3 micromolar respectively Grippo 2021. That last number is the one that matters and nobody quotes it: above its critical micellar concentration a nitroalkene aggregates instead of dissolving, so its free, reactive concentration stops rising with dose. An electrophile has a ceiling built into its physical chemistry.
Step two, in rodents. Salicylate has real rodent metabolic data Kajani 2022. Futile-cycle biology has real rodent data Bunk 2025. There is no rodent study of this compound.
Step three, in humans. There is nothing. No PubMed entry for MVD-1, no trial registry record, no published pharmacology, no certificate of analysis in the public domain, no CAS number on the vendor's own reference page. The obstacle is not that translation is hard. It is that there is nothing to translate. Everything above describes what a nitroalkene salicylate would be expected to do from its chemical class, and what the creatine cycle is known to do in mice. Connecting the two is an assumption somebody is charging for.
SANA pharmacokinetics — how much of it actually gets in
The card says half-life unknown, and that is honest. What follows is the arithmetic that bounds it, which is content the blank is not.
What degrades it, part one: the electrophile. A nitroalkene is cleared primarily by conjugation to glutathione, and human glutathione transferases catalyze that reaction directly Steglich 2025. This has a consequence no dosing table captures: the clearance of an electrophile is set by the size of the glutathione pool, not by an enzyme's Vmax alone. Anything that depletes glutathione — acetaminophen, alcohol, a heavy oxidative load — slows clearance and raises exposure, and does so non-linearly.
What degrades it, part two: the salicylate. Salicylates are cleared by hepatic conjugation — glucuronidation of both the phenolic and carboxyl groups plus glycine conjugation to salicyluric acid — with the remainder by renal clearance of unchanged drug. Both conjugation routes are saturable, which is why salicylate kinetics are famously dose-dependent: below saturation the half-life is a few hours; above it, the same molecule can persist for 15–30 hours. If MVD-1 releases a salicylate, its elimination is not first-order and a single half-life number could not describe it even if someone measured one.
The oral barrier. An oral capsule meets gastric acid, then the gastrointestinal wall, then first-pass metabolism in the liver. For an electrophile, the gut and portal blood are full of thiols, so a meaningful share of the dose is conjugated before it reaches the systemic circulation — oral bioavailability for this chemical class is expected to be low and variable. For a salicylate ester, hydrolysis by plasma and hepatic esterases is the activation step, so the parent may never be the active species at all.
Numbers, and where they come from. The only measured concentrations in this space are the micellar thresholds above — 6.9 to 42.3 micromolar Grippo 2021. A 50 mg capsule distributed into roughly 40 liters of body water, before any clearance at all, gives an upper bound in the low micromolar range for a molecule of a few hundred daltons. That is the same order as the concentration at which nitroalkenes stop behaving as free monomers. It is a crude calculation and it is the only one available, and it says the dose sits exactly where the physical chemistry gets complicated.
The injectable comparator, which does not exist. Nothing in this class has been injected into a person for this purpose, so there is no route by which to check how much of the oral dose is lost. Without an intravenous or subcutaneous comparator, absolute bioavailability cannot be computed for any compound — which means the honest answer to “how much gets in” is uncomputable, not small.
What would have to be true, and how you would know it was not
Three predictions. The first is what the marketed mechanism demands, the second is what the actual chemistry demands, and the third argues against the product.
1. If the futile creatine cycle is engaged, resting energy expenditure has to rise, and nothing else needs to. The claim is thermogenesis without appetite suppression Kazak 2023. That makes it unusually testable without a lab: measure resting metabolic rate by indirect calorimetry at baseline and at 6 weeks, hold body weight and food intake constant, and look for a rise of more than the measurement error. A futile cycle that produces heat and does not touch intake is one of the few fat-loss claims with a clean, single-variable read-out. Nobody has published one for this compound.
2. If the salicylate half is doing anything, hs-CRP should fall and uric acid should move. Salicylate suppresses inflammatory signaling in adipose tissue Kajani 2022, and salicylates compete with urate for renal tubular transport, so urate handling shifts in a dose-dependent and direction-dependent way. Draw hs-CRP and uric acid at baseline and 8 weeks. A falling hs-CRP with a moved urate is the signature of a salicylate at a systemically active dose — and it would be the first confirmation that the capsule contains a pharmacologically meaningful amount of one.
3. The prediction that cuts against it: a CMP should show nothing, and if it shows nothing the product has no demonstrated systemic activity at all. Draw a CMP and a lipid panel at baseline and 8 weeks. Flat liver enzymes, flat bicarbonate, flat lipids, an unchanged resting metabolic rate and an unchanged hs-CRP would mean the dose is doing nothing measurable, which for a $149.99 bottle with no published pharmacology is the single most likely outcome and the one this page will not hide.
What nobody has tested yet
Four experiments, listed in order of how cheaply they would settle the question.
Nobody has independently identified what is in the capsule. There is no CAS number, no structure, no formula and no certificate of analysis in the public domain. A single liquid-chromatography mass-spectrometry run on one capsule would establish the molecular weight and formula and would tell you more than everything else on this page combined. That is a routine commercial assay costing a couple of hundred dollars.
Nobody has measured urinary or plasma creatine and creatinine on any putative creatine-cycle drug. If the cycle is running faster, creatine turnover changes, and creatinine is the non-enzymatic breakdown product of phosphocreatine produced at a rate proportional to the pool size. A CMP-based creatinine trajectory, with muscle mass and kidney function held constant, is the closest thing to a free biomarker this mechanism has, and it has never been used as one.
Nobody has resolved which creatine kinase carries the cycle in humans. Two good papers disagree about whether the mitochondrial isoform is even required Bunk 2025 Politis-Barber 2022, and the argument is entirely in mice. Whether human white or brown adipose does this at all is unsettled, and a human adipose biopsy study with respirometry would settle it.
Nobody has asked whether an electrophile at this dose depletes glutathione measurably. The clearance route is glutathione conjugation Steglich 2025. If a daily dose is large relative to the pool, the compound is a chronic oxidative load rather than a metabolic drug, and whole-blood glutathione is measurable. That question has not been asked of any consumer nitroalkene product.
SANA — its own safety story, not its class's
The specific risk here is not the mechanism. It is that nothing about this molecule is known, and the two chemical classes it claims membership in both have real, characterized toxicities.
Salicylate toxicity is dose-dependent and its early signs are easy to miss. Because salicylate conjugation saturates, exposure rises faster than dose once the enzymes are full. The classic early features — ringing in the ears, faster breathing, nausea — are the ones a user is most likely to attribute to something else. And the reason salicylate raises body temperature at high concentration is that it uncouples oxidative phosphorylation, which is a thermogenic mechanism, and not the flattering one: it is the mechanism that made dinitrophenol lethal. A product sold for thermogenesis that may contain a salicylate deserves that sentence said out loud.
Electrophiles are not neutral. A molecule whose pharmacology is covalent modification of cysteine thiols Grippo 2021 is, by construction, a molecule that consumes glutathione Steglich 2025. In a person who also drinks, or takes acetaminophen, or has any degree of hepatic compromise, that competition is real and it goes in one direction. There is no published human dose at which this is known to be safe, because there is no published human dose.
The supply risk is the specific one, and it is unusually concrete here. The Vault's own note records that the vendor's research page for this product carries no CAS number, no formula and no mechanism — only marketing keywords — while every other compound in the same batch has a real reference page. That is not a judgment about the seller; it is an observation about how much is verifiable, which is nothing.
What reduces risk here, mechanistically. Nothing about injection technique applies; this is an oral capsule. The measures that follow from the chemistry above are: run a CMP before starting so a liver signal has a baseline to be compared against, do not combine it with regular acetaminophen or alcohol while the clearance route is glutathione, avoid it entirely alongside any other salicylate or an anticoagulant, and treat any ringing in the ears as a stop signal rather than a curiosity.
Sources read for this page
- Bunk J, et al. The Futile Creatine Cycle powers UCP1-independent thermogenesis in classical BAT. Nature Communications 2025 · PMID 40185737
- Politis-Barber V, et al. Ckmt1 is Dispensable for Mitochondrial Bioenergetics Within White/Beige Adipose Tissue. Function (Oxford) 2022 · PMID 37954502
- Kazak L, et al. Promoting metabolic inefficiency for metabolic disease. iScience 2023 · PMID 37736043
- Brownstein AJ, et al. ATP-consuming futile cycles as energy dissipating mechanisms to counteract obesity. Reviews in Endocrine and Metabolic Disorders 2022 · PMID 34741717
- Grippo V, et al. Electrophilic characteristics and aqueous behavior of fatty acid nitroalkenes. Redox Biology 2021 · PMID 33181478
- Steglich M, et al. Human glutathione transferases catalyze the reaction between glutathione and nitrooleic acid. Journal of Biological Chemistry 2025 · PMID 40024478
- Kajani S, et al. Sodium salicylate rewires hepatic metabolic pathways in obesity and attenuates IL-1beta secretion from adipose tissue. Molecular Metabolism 2022 · PMID 34954383
SANA — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- Two chemistries are named in one description and each brings its own predicted problem. The salicylate arm predicts what salicylates predict: GI irritation and ulceration, bleeding risk, and tinnitus as the classic early signal of too much.
- The thermogenic arm is the one to take seriously. A compound sold for thermogenesis is a compound sold for turning substrate into heat instead of ATP. The description here is a creatine futile cycle, which would be a gentler mechanism than mitochondrial uncoupling — but nobody has demonstrated which of the two it actually does, and the failure mode of the harsher version is hyperthermia, which is the mechanism that makes DNP lethal. That is not a claim that this compound is DNP. It is the reason a thermogenic with no published pharmacology deserves more caution than one with a known mechanism, rather than less.
- If it raises heat production at all, then hot environments, hard training and dehydration all stack with it — and none of those will feel like the compound while they are happening.
What has actually been reported
- Nothing. No PubMed entry, no trial registry record, no published pharmacology for MVD-1 in any form.
- One credibility signal is worth stating plainly: the vendor's own reference page for this compound carries no CAS number, no formula and no mechanism — only marketing strings. Every other compound in this batch has a real reference page. This is the weakest evidence position of any card in the Vault and this section should be read that way.
How to reduce the risk
Same mechanism as the prediction.
- With no literature to compare a reaction against, your own baseline and a single variable are the only instruments you have. Change nothing else at the same time — that advice is generic everywhere else on this site and specific here.
- Stop for tinnitus, ringing, or new GI pain. Those are the salicylate signals and they arrive before the serious version does.
- Do not run it in heat, dehydrated, or alongside another thermogenic. If your resting heart rate or temperature is measurably up, that is the mechanism reporting in rather than a coincidence — and it is a reason to stop rather than to push.
What it does to your bloodwork
A fact about the assay.
- A full blood count and a metabolic panel, with liver enzymes — a baseline before, so that anything measured later has something to be compared against. With no literature to consult, your own before-and-after is the only comparison available.
Don't run this if
- You take an anticoagulant or antiplatelet, or have any history of GI ulcer or bleeding — the salicylate arm.
- Aspirin sensitivity, or asthma with nasal polyps, which is the salicylate-sensitive phenotype.
- Children and teenagers — salicylates and Reye's syndrome.
- You have surgery scheduled.
- You train in heat, or you cannot reliably distinguish overheating from working hard. Those are the conditions under which the predicted failure mode is least likely to be noticed in time.
The honest unknown
- Whether the compound does what the description says at all. Not the dose, not the duration — the mechanism itself is unverified, and every line above is conditional on a story the seller is telling.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
SANA — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What SANA moves on your bloodwork
Expected direction, not a measured one.
- TSH (Thyroid-Stimulating Hormone) — ↓ expected to fall
Exogenous thyroid hormone or a thyromimetic suppresses TSH by feedback. A suppressed TSH here is the expected consequence, not evidence of thyroid disease.
What to do: TSH alone is uninterpretable on these. Run free T3 and free T4 with it or the panel means nothing. - Free T3 (Triiodothyronine) — ↑ expected to rise
Rises with dosing, and this is the number driving both the benefit and the risk.
What to do: The gap between 'metabolically effective' and 'losing muscle and beating up your heart' is narrow. Test, don't estimate. - Complete Blood Count (CBC) with Differential — ◆ worth watching
Not the marker itself — but resting heart rate and blood pressure are the real-time readouts of over-dosing here, and they move before any lab does.
What to do: Take a resting heart rate every morning. It is a better early signal than a quarterly panel. - Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Uncouplers and strong thermogenics raise metabolic demand and can stress liver enzymes.
What to do: Baseline liver function before, and again at 8 weeks.
- Dose range and how to work up to it
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — SANA in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside SANA
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| HbA1c (Hemoglobin A1c) | Where you started, so you can prove the change was real |
| Fasting Insulin | Moves years before HbA1c does — the earliest signal you get |
| Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) | Rapid fat loss shifts triglycerides fast, in both directions |
| Comprehensive Metabolic Panel (CMP) | Liver, kidney and electrolytes while intake is restricted |
The Metabolic Health & Prediabetes panel covers these in one order — 8 markers, $81.45 with the discount applied.
Check results you already have → · All 103 markers A–Z
SANA — frequently asked questions
What is SANA?
SANA (MVD-1 — nitroalkene / salicylate derivative) is a metabolic & fat loss research compound. Sold as a nitroalkene / salicylate derivative studied for creatine-associated thermogenesis and mitochondrial substrate handling. The creatine angle is the interesting part: creatine cycling between phosphocreatine and creatine can act as a futile cycle that burns ATP as heat rather than storing it, and that is a genuinely different fat-loss lever from appetite suppression or beta-adrenergic stimulation. Everything in that sentence comes from the vendor's own description. No published pharmacology for MVD-1 was found.
Where can I find SANA dosing and protocols?
Dosing, the reconstitution calculator and Coach Cam's full SANA protocol are available to members inside Skool. This public page covers what SANA is, how it works and the evidence.
What is the half-life of SANA?
SANA has an approximate half-life of Unknown, which is part of what determines how often it's dosed.
What's the evidence behind SANA?
Current evidence level: None independent — vendor description only. No PubMed entry, no trial registry record.. SANA is offered for research purposes only and is not an approved medicine.
What SANA is used for
SANA appears under 1 goal in the goal router.
Related Metabolic & Fat Loss compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.